Related Experiment Video
Updated: Apr 1, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Venous thrombosis in patients with high-grade glioma
Sophie Taillibert1, Luc Taillandier, Emilie Le Rhun
1aNeurologie Department - Pitié-Salpétrière Hospital, Paris VI Pierre and Marie Curie University, Assistance Publique des Hôpitaux de Paris-Paris bNeuro-oncology Unit, Neurooncology Department, Nancy University Hospital, Central Hospital and CRAN UMR 7039 CNRS, SBS BEAM Department, Nancy University, Vandœuvre-lès-Nancy cNeuro-oncology Department, University Hospital dMedical Oncology Department, Oscar Lambret Center, Lille eINSERM U1192, PRISM Laboratory, Lille University, Villeneuve d'Ascq, Laboratoire PRISM, France.
Purpose Of Review:
High-grade glioma (HGG) patients are at particularly high risk of venous thromboembolism (VTE) occurrence and recurrence. VTE is associated with worsened survival in these patients. At present, the main challenge when prescribing anticoagulants in HGG patients is to address the risk of intracranial hemorrhage and provide the optimal treatment.
Recent Findings:
Here, we discuss the latest biological findings and their potential implications for better classification in daily practice and stratification of patients in future trials according to their risk of developing a VTE.
Summary:
To help clinicians, international guidelines have been provided for cancer patients, but their implementation remains suboptimal. We report here the specificities of VTE management in HGG patients relative to other cancer patients. Particular aspects such as anticoagulation under targeted therapies, primary and secondary prophylaxis, and the role of new oral anticoagulants are discussed as well.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis I: Introduction
Venous Thrombosis IV: Nursing Management
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

